Skip to main content
All lobbying filings

CROSSROADS STRATEGIES, LLC

CROSSROADS STRATEGIES, LLC filed a Q3 report for TAKEDA PHARMACEUTICALS AMERICA, INC. on October 17, 2026, reporting $50,000 in lobbying income.

Lobbying for TAKEDA PHARMACEUTICALS AMERICA, INC. · pharmaceutical company

All filings by CROSSROADS STRATEGIES, LLC · Everything TAKEDA PHARMACEUTICALS AMERICA, INC. has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 17, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
Illinois

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Issues related to tax reform; international taxation.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

 Bills named in this filing 1
  • S. 891
    Bipartisan Health Care Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem